Bromodomain Inhibitors BD1 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective bromodomain inhibitors that specifically target the binding of BET family bromodomains to acetylated lysine residues, particularly through the Binding Domain 1 (BD1), which is crucial for regulating gene transcription and is implicated in various diseases including autoimmune disorders, inflammatory conditions, and cancers.
Innovation Solution
Development of novel compounds of formula (I) and their pharmaceutically acceptable salts, which act as selective inhibitors of BET family bromodomains by disrupting their binding to acetylated lysine residues, particularly through the BD1 domain, thereby modulating chromatin structure and gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment of autoimmune diseases, inflammatory conditions, and cancers is attempted, but effective inhibition of BET family bromodomains binding to acetylated lysine residues is not achieved
Solution Approach 1:
The invention segments the bromodomain binding interface into specific functional regions, designing compounds that selectively target the BD1 domain of BET proteins. This segmentation allows for precise inhibition of pathogenic bromodomain-acetylated lysine interactions while preserving other cellular functions, thereby achieving reliable therapeutic effectiveness for autoimmune diseases, inflammatory conditions, and cancers.
Solution Approach 2:
The invention employs parameter changes in the chemical structure of bromodomain inhibitors, specifically modifying the heterocyclic core and substituent groups to optimize binding affinity and selectivity for BET family bromodomains. These parameter changes enable effective inhibition of the bromodomain-acetylated lysine interaction, resolving the lack of effective inhibitors in current therapies.
2Measurement precision
If selective inhibition of BD1 domain is achieved, then specific regulation of gene transcription is improved, but compound structure complexity increases
Solution Approach 1:
The invention applies local quality by designing compounds with specific functional groups and heterocyclic structures that selectively interact with the BD1 domain of BET bromodomains. The molecular structure incorporates specific pharmacophoric elements positioned to recognize and bind the acetylated lysine motif with high selectivity, achieving precise regulation of gene transcription without requiring excessive overall molecular complexity.
Solution Approach 2:
The invention employs preliminary action by pre-organizing the molecular structure of the bromodomain inhibitor to match the binding geometry of the BD1 domain and acetylated lysine residues. This pre-organization reduces the entropic penalty upon binding and enhances selectivity, allowing specific BD1 inhibition with optimized rather than excessively complex structures.
Data Source
AI summary
The present invention relates to novel compounds, pharmaceutical compositions containing such compounds and to their use in therapy.